Skip to main content

Table 3 Antioxidant activity of the synthesized analogous

From: Design, synthesis and biological potentials of novel tetrahydroimidazo[1,2-a]pyrimidine derivatives

Comp. % Inhibition IC50 µg/ml
25 µg/ml 50 µg/ml 75 µg/ml 100 µg/ml
1 30.56 42.68 55.52 76.45 60.30
2 37.25 51.23 67.34 89.45 46.31
3 20.62 35.93 56.24 69.85 68.90
4 15.71 33.96 43.59 65.21 78.60
5 21.73 37.39 58.72 73.24 65.60
6 25.65 30.95 51.34 67.28 72.70
7 14.59 24.78 47.64 59.45 83.20
8 26.34 37.31 55.28 72.52 65.80
9 32.62 48.28 65.21 82.16 51.83
10 28.89 45.85 60.27 72.56 59.20
11 26.73 47.19 63.81 79.34 56.40
12 17.62 42.95 56.57 68.28 67.80
13 32.47 47.61 64.92 78.52 53.06
14 19.53 41.63 61.57 74.82 63.30
15 22.68 39.91 57.74 71.73 65.40
16 35.95 53.23 62.58 78.84 48.81
17 24.64 43.98 61.37 74.81 60.70
18 32.94 48.92 59.38 72.49 55.90
19 19.62 43.81 61.52 74.49 62.60
20 21.71 34.61 56.70 75.82 66.24
21 15.25 33.41 47.43 65.51 77.00
22 19.26 33.16 50.16 69.25 72.90
23 23.67 47.28 65.11 78.26 57.65
24 23.68 47.28 56.14 72.61 62.60
Ascorbic acid 39.52 55.74 68.25 93.61 42.52